Key facts
- This page summarizes Adam Koppel's Form 4 filing for Foghorn Therapeutics Inc. (FHTX).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 28 Jun 2024, 16:00.
Adam Koppel - 26 Jun 2024 Form 4 Insider Report for Foghorn Therapeutics Inc. (FHTX)
- Reporting relationship
- Director
- Issuer ticker
- FHTX
- Reported as of
- 26 Jun 2024
- Net transaction value
- +$88,320
- SEC form
- 4
- Accepted by SEC
- 28 Jun 2024, 16:00:47 UTC
- Prior SEC filing
- 07 Jun 2024
- Next SEC filing
- 05 Aug 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael LaCascia, Attorney-in-Fact for Adam Koppel
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Adam Koppel filed Form 4 for Foghorn Therapeutics Inc. (FHTX) on 28 Jun 2024.
Change
- Previous filing in this sequence was filed on 07 Jun 2024.
- Current net transaction value: +$88,320.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
FHTX
transaction
Derivative
Stock Options (Right to buy)
Award
- Transaction value
- $88,320
- Shares
- +16,000
- Change %
- Price
- $5.52
- Shares after
- 16,000
- Date
- 26 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 16,000
- Exercise price
- $5.52
* marks a reported price that did not pass the local price check.